Analysts expect Vivani Medical to report a loss of $0.08 per share on zero revenue for Q2 2026, with the stock currently trading near $1.40 against a consensus price target of $3.75. Investors are primarily focused on clinical progress updates for the SLIM-1 Phase 1 trial of the company's semaglutide implant, NPM-139, which recently achieved full enrollment.
Sentiment has been significantly bolstered by a July 2026 agreement with Novo Nordisk to evaluate the proprietary NanoPortal implant technology for chronic weight management. Successful execution of the SLIM-1 trial is seen as a major catalyst for the company's transition from a preclinical platform to a key participant in the competitive GLP-1 market.